Article Text

Download PDFPDF

586 Impact of SARS-CoV-2 infection on treatment results in patients with epithelial ovarian cancer
  1. S Piątek and
  2. M Bidzinski
  1. maria sklodowska curie national research institute of oncology, gynecologic oncology, warsaw, Poland


Introduction/Background*Continuity of care has become a priority for cancer patients during COVID-19 pandemic. To protect oncological wards from pandemic outbreaks, all patients were tested for SARS-CoV-2 infection before admission. However, some asymptomatic patients were diagnosed with SARS-CoV-2 infection. Due to the obligatory isolation, treatment of positive patients had to be postponed. Only patients with negative result were admitted to the hospital and continued the treatment. Some of the patients got > 1 positive result and treatment delay was additionally extended. The purpose of this study was to evaluate treatment outcomes in ovarian cancer (OC) patients with confirmed infection of SARS-CoV-2.

Methodology The qualification scheme for the observational study was presented in figure 1.

Result(s)*Out of 235 patients, 198 were eligible for the study. Primary and recurrent OC were diagnosed in 88 (44.45%) and 110 (55.55%) patients, respectively. A total of 16 (8.1%) patients were positive for SARS-CoV-2: 9 (10.2%) patients with primary OC and 7 (6.4%) patients with recurrent disease. The median time of treatment postponement was 29.5 (10-42) days.

Of 88 patients with primary disease: 8 started treatment before the pandemic and completed chemotherapy during the pandemic, 62 started and completed treatment during the pandemic, 18 started treatment during the pandemic and are at the moment during therapy. In these patients, infection of SARS-CoV-2 were found in 0, 8 (12.6%) and 1 (5.55%) patients, respectively.

Among 62 patients who underwent cancer treatment during the pandemic the median CA-125 nadir levels were 18.05 U/ml (10.5-473 U/ml) for 8 SARS-CoV-2 positive and 14.5 U/ml (4.8-2300 U/ml) for 54 SARS-CoV-2 negative patients. Complete response, partial response, stable disease and progression among positive patients were diagnosed in 3 (37.5%), 2 (25%), 1 (12.5%) and 2 (25%) cases respectively and among SARS-CoV-2 negative patients were found in 25 (46.3%), 21 (38.9%), 4 (7.4%), 4 (7.4%) patients respectively.

Conclusion*Diagnosis of SARS-CoV-2 infection may have negative impact on treatment results of OC patients. Undoubtedly, COVID-19 pandemic has a negative effect on the treatment duration of patients with OC (indirect effect on treatment outcome). However, it is unknown if SARS-CoV-2 has any direct effects on tumor growth or other indirect effects - change in response to treatment or influence on drug effectiveness.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.